Actively Recruiting
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
Led by Jordan Kharofa · Updated on 2026-02-27
21
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.
CONDITIONS
Official Title
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- ECOG performance status of 0 to 2 or Karnofsky score 60% or higher
- Adequate organ and marrow function to receive immunotherapy and/or chemoimmunotherapy
- Planned and able to undergo active PD-L1 or PD-1 checkpoint immunotherapy throughout radiation treatment
- Biopsy confirmed non-small cell lung cancer or melanoma
- Radiographic evidence of liver metastases
- Women of child-bearing potential and men must use effective contraception during the study
- Ability to understand and sign informed consent or have a legally authorized representative do so
- Must have insurance approval for radiotherapy before starting radiation on the study
You will not qualify if you...
- Prior immunotherapy in the adjuvant setting within 6 months before enrollment
- NSCLC patients with driver mutations EGFR, ALK, ROS1, or RET are not eligible for cohort 1
- Uncontrolled illness or other significant conditions that increase risk as judged by the investigator
- Prior or concurrent malignancy that may interfere with safety or effectiveness assessments
- Pregnant women are excluded due to use of ionizing radiation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45219
Actively Recruiting
Research Team
U
UCCC Clinical Trials Office
CONTACT
J
Jordan Kharofa, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here